论文部分内容阅读
吉姆单抗/奥佐米星(GO)由人源化IgG4抗CD33单克隆抗体与细胞毒药物刺孢霉素的衍生物结合形成,为美国Wyeth公司生产。2000年5月美国食品及药品管理局(FDA)批准GO单药治疗年
Gemcitabine / ozogamicin (GO) is formed by the combination of a humanized IgG4 anti-CD33 monoclonal antibody with a derivative of the cytotoxic calicheamicin, manufactured by Wyeth, USA. May 2000 US Food and Drug Administration (FDA) approved GO monotherapy years